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INTRODUCTION:Renal cell carcinoma (RCC)with t(6:11) (p21;q12) are extremely rare, fewer than30cases
have been reported in literature. These tumors are characterized by speciﬁc chromosomal translocation
involving TFEB, as against the more commonly known TFE3 (Xp11.2) translocation associated RCCs. The
distinctive immnohistologic features are helpful in enabling a diagnosis of this rare tumor, otherwise
diagnosed by ﬂuorescence in situ hybridization assay, speciﬁc for detecting TFEB gene rearrangement.
PRESENTATION OF CASE: Herein, we report a case of this rare tumor in a 11 years old boy, with the objec-
tive of highlighting distinctive lightmicroscopic and immuno-phenotypic features of this rare sub-type of
translocation associated renal cell carcinoma, otherwise diagnosed by ﬂuorescence in situ hybridization
technique. Morphologically tumor showed distinctive biphasic population of cells, large epitheloid cells
with voluminous eosinophillic cytoplasm and smaller cells with much lesser amount of cytoplasm and
small rounded nuclei. The smaller cells at places clustered around hyaline pink material forming “pseu-
dorosettes”. population. Immunohistochemically both types of tumor cells showed negativity for pan CK
(cytokeratin), EMA (epitheleal membrane antigen) and TFE3 (transcription factor E3). HMB 45 (human
melanoma black 45) and Melan- A /MART 1 (melanoma antigen recognized by T cells) were moderate to
strongly expressed.
DISCUSSION: On review of literature, most RCCs with t(6;11) translocation have been reported to be
negative for pan cytokeratins andEMA. Published literature also shows that themost distinctive immuno-
histochemical feature of t(6;11) translocation RCC is nuclear staining for TFEB protein. Immunostains
for TFE3 have always been negative in the reported cases. It is noteworthy that immunoreactivity for
melanocytic markers HMB45 and Melan A and immunonegativity for epithelial markers pan CK and EMA
may lead to misdiagnosis of angiomyolipoma to the unwary.
CONCLUSION: Knowledge of distinctive morphological and immuno-histochemical features of this tumor
can help in establishing a diagnosis of this rare subset of translocation associated RCC on routine hema-
toxylin and eosin (H and E) staining and immunophenotyping.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Renal cell carcinoma (RCC)with t(6:11) (p21;q12) are extremely
rare, fewer than 30 cases have been reported in literature [1–3].
These tumors are characterized by a speciﬁc chromosomal translo-
cation involving the transcription factor EB (TFEB) [4]. This
distinctive tumor was ﬁrst described by Argani et al. [4]. Increasing
evidence has shown that these tumors possess uniquemorphologic
and immunohistochemical features. The identiﬁcation of overex-
pression of TFEB protein by immunohistochemistry or detecting a
t(6:11) (p21;q12) translocation by ﬂuorescence in situ hybridiza-
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tion is necessary for accurate diagnosis [5]. We hereby present a
case report of this rare tumor in a 11year old boy,with the objective
of highlighting its distinctive immuno-histologic features.
2. Case report
Patient, a 11 years old boy, presented at our institute with com-
plaints of lump in the right hypochondrium noticed since last 10
days. He also complained of fever since last 10 days. No history of
trauma or any other signiﬁcant past history was reported. An ultra-
sound study revealed a large heterogeneous appearing mass lesion
arising from upper and mid pole of the right kidney with increased
vascularity. CT scanshoweda largeheterogenouslyenhancingmass
lesion arising from the upper pole of right kidney with arterial
enhancement and washout on delayed phases, suggestive of neo-
plastic etiology. A possibilty of Renal Cell Carcinoma or Wilm’s
Tumor was suggested.
http://dx.doi.org/10.1016/j.ijscr.2014.12.026
2210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) Gross ﬁndings on Nephrectomy specimen: large well-delineated, nodular, tan- brown colored tumor nearly completely replacing the normal renal parenchyma.
(B) H and E10× (C) H and E 20×: biphasic population of cells, large epitheloid cells with voluminous eosinophillic cytoplasm and smaller cells with much lesser amount of
cytoplasm and small rounded nuclei. (D) The smaller cells at places clustered around hyaline pink material forming “pseudorosettes”.
A right radical nephrectomy was performed and sent for
histopathological examination. Bisected kidney showed a large
well-delineated, nodular, tan- brown colored, soft to ﬁrm tumor
measuring 13.7×11.0×8.0 cm, nearly completely replacing the
normal renal parenchyma (Fig 1A). No necrosis was identiﬁed.
Morphology revealed a biphasic population of cells (Fig 1B and
C), large epitheloid cells with voluminous eosinophilic cytoplasm
and smaller cells with much lesser amount of cytoplasm and small
rounded nuclei. The smaller cells at places clustered around hya-
line pink material forming “pseudorosettes”(Fig 1D). Dark brown
pigmentationwas observed in small cell population. Immunohisto-
chemically (Fig 2A–E) both types of tumor cells showed negativity
for pan CK (cytokeratin), EMA (epitheleal membrane antigen) and
TFE3 (transcription factor E3). HMB 45 (human melanoma black
45) and Melan A/MART 1 (melanoma antigen recognized by T cells)
were moderate to strongly expressed. Subsequently, ﬂuorescence
in situ hybridization studies done at an outside referral institute
showed t(6:11) (p21;q12) renal cell carcinoma.
3. Materials and method
Tissue was ﬁxed in 10% neutral buffered formalin and embed-
ded in parafﬁn. Immunohistochemical analysis was done using
following antibodies: pan CK (AE1 and AE3,Biogenex), EMA (E29,
Biogenex), TFE3 (MRQ-37, Cell Marque, 1:100), HMB45 (HMB45,
Biogenex), and Melan A (Clone A103, Dako). Immunoreaction was
performed using the Horse Radish Peroxidase- conjugated strep-
tavidin (Biogenex Polymer HRP kit). Diaminobenzidine (DAB) was
used as chromogen.
4. Discussion
t(6:11) (p21;q12) associated RCCs are rare subsets of the dis-
tinctive entity of translocation associatedRCCs as described in 2004
WHO classiﬁcation of renal tumors [6]. These translocations most
frequently involve the TFE3 gene on locus Xp11.2 and less fre-
quently involve the TFEB gene on locus 6p21 [7]. Less than 30
cases of t(6:11) (p21;q12) associated RCCs have been reported in
literature [1–3]. Recently Rao et al. reported additional 7 cases [8].
The translocation of t(6;11)(p21;q12 or q13) causes fusion of Alpha
gene on 11q12 or q13 with the TFEB gene on 6p21, this results in
overexpressionofnativeTFEBprotein. Reviewof thepublisheddata
indicates that RCCwith t(6;11) translocation is seen predominantly
in childrenandyoungadults,minorityofpatientsbeingolder adults
[9]. The patient in our case is 11 years old. Microscopically as in
our case biphasic pattern of tumor, constituted by large epitheloid
cells with voluminous pink cytoplasm and smaller cells centered
around hyaline material, so called ‘pseudorosette’ pattern was the
most common pattern. Published literature also shows that the
most distinctive immunohistochemical feature of t(6;11) translo-
cation RCC is nuclear staining for TFEB protein [10–12]. Argani et al.
[2] detected strong nuclear TFEB labeling in all seven RCCs with
t(6;11) translocation studied, in contrast to 1089 other unrelated
neoplasms and normal tissues that showed negativity for nuclear
labeling of this protein. Noteworthy fact is that melanocytic mark-
ers HMB45 and Melan-A are commonly positive in these tumors
[4,5]. Moderate to strong expression of HMB45, and Melan-A was
seen in our patient case as well. TFEB was however not performed
in our case. Most RCCs with t(6;11) translocation are negative for
pan cytokeratins and EMA. Only four patient cases have been pos-
itive for pan CK [1,3,12] and two have been positive for EMA [5].
CASE REPORT – OPEN ACCESS
18 S.K. Arneja, N. Gujar / International Journal of Surgery Case Reports 7 (2015) 16–19
Fig. 2. Immunohistochemistry: (A–C) pan CK, EMA and TFE3, respectively. Immunonegative for pan CK, EMA and TFE3. Note nuclear nonreactivty for TFE3. (D) HMB45 and
(E) Melan A. Immunopositivity for HMB45 and Melan A.
Immunostains for TFE3 have always been negative in the reported
cases [1,2,4,5,9–11] It is noteworthy that immunoreactivity for
melanocytic markers HMB45 and Melan A and immunonegativity
for epithelial markers pan CK and EMA may lead to misdiagnosis of
Angiomyolipoma to the unwary [9]. This tumor is so far a patholo-
logically andmolecularly deﬁnedentity. Due to its rarity the clinical
behavior of these tumors remains uncertain. One such case study
of 7 cases where follow up was available on 6 cases, has shown
no evidence of recurrent disease or disease progression after ini-
tial surgical resection, indicating thereby that this may represent
an indolent tumor [8]. Our case also has been followed up for one
year and is free of recurrent disease. However the available data
represent a small sample and a short term follow up and may not
represent the true nature of these tumors.
In conclusion, knowledge of distinctive morphological and
immunohistochemical features of this tumor can help in establish-
ing a diagnosis of this rare subset of translocation associatedRCCon
routine hematoxylin and eosin (H and E) staining and immunophe-
notyping.
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